We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+10.78%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.58B
AUM Growth
+$312M
Cap. Flow
+$159M
Cap. Flow %
6.16%
Top 10 Hldgs %
33.71%
Holding
96
New
19
Increased
23
Reduced
16
Closed
13

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$59M
2
SYK icon
Stryker
SYK
+$39M
3
ALKS icon
Alkermes
ALKS
+$34.9M
4
ICLR icon
Icon
ICLR
+$31.7M
5
ABBV icon
AbbVie
ABBV
+$31.6M

Top Sells

Rank Stock Value
1
QURE icon
uniQure
QURE
+$38.8M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$35.7M
3
AVTR icon
Avantor
AVTR
+$28.6M
4
ASND icon
Ascendis Pharma A/S
ASND
+$21.7M
5
ICUI icon
ICU Medical
ICUI
+$20.2M

Sector Composition

Rank Sector Weight
1 Healthcare 94.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ERAS icon
51
Erasca
ERAS
$6.3B
$13.2M 0.51%
4,797,460
– –
PNT
52
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$11.8M 0.46%
1,299,491
-1,905,299
-59% -$16.8M
ABCM
53
DELISTED
Abcam PLC
ABCM
$11.7M 0.45%
+476,430
New +$8.22M
EPIX
54
DELISTED
ESSA Pharma
EPIX
$11.4M 0.44%
4,204,953
+43,492
+1% +$128K
FXI icon
55
CALL
iShares China Large-Cap ETF
FXI
$4.37B
$11M 0.43%
+405,400
New +$11.4M
FXI icon
56
iShares China Large-Cap ETF
FXI
$4.37B
$10.8M 0.42%
+398,720
New +$11.2M
PRCT icon
57
Procept Biorobotics
PRCT
$1.06B
$10.4M 0.41%
295,544
-24,238
-8% -$801K
PRAX icon
58
Praxis Precision Medicines
PRAX
$8.58B
$10.2M 0.4%
592,784
+447,678
+309% +$6.85M
ACLX
59
DELISTED
Arcellx
ACLX
$8.09M 0.31%
255,832
-269,984
-51% -$10.3M
ADAP
60
DELISTED
Adaptimmune Therapeutics
ADAP
$7.73M 0.3%
8,357,242
+2,364,671
+39% +$2.82M
VEEV icon
61
Veeva Systems
VEEV
$33.1B
$7.4M 0.29%
+37,421
New +$6.82M
IMVT icon
62
Immunovant
IMVT
$7.93B
$7.38M 0.29%
388,918
-73,513
-16% -$1.37M
HOWL icon
63
Werewolf Therapeutics
HOWL
$17.2M
$7.03M 0.27%
2,303,891
+86,671
+4% +$244K
VRDN icon
64
Viridian Therapeutics
VRDN
$2.09B
$6.97M 0.27%
+293,140
New +$7.52M
ZLAB icon
65
Zai Lab
ZLAB
$2.06B
$6.84M 0.27%
+246,706
New +$8.07M
IOVA icon
66
Iovance Biotherapeutics
IOVA
$1.82B
$6.66M 0.26%
946,305
+804,250
+566% +$5.76M
RCKT icon
67
Rocket Pharmaceuticals
RCKT
$340M
$4.74M 0.18%
+238,762
New +$4.82M
ROIV icon
68
Roivant Sciences
ROIV
$24.5B
$3.88M 0.15%
+384,991
New +$3.44M
XENE icon
69
Xenon Pharmaceuticals
XENE
$6.06B
$3.86M 0.15%
100,147
– –
EDIT icon
70
Editas Medicine
EDIT
$396M
$3.63M 0.14%
441,170
-599,624
-58% -$5.22M
VERV
71
DELISTED
Verve Therapeutics
VERV
$3.49M 0.14%
186,087
– –
INBX
72
DELISTED
Inhibrx, Inc. Common Stock
INBX
$3.32M 0.13%
127,703
+6,256
+5% +$146K
CELC icon
73
Celcuity
CELC
$4.21B
$2.83M 0.11%
257,713
-53,252
-17% -$553K
OSCR icon
74
Oscar Health
OSCR
$9.41B
$2.71M 0.11%
+336,166
New +$2.48M
IRTC icon
75
CALL
iRhythm Holdings
IRTC
$3.85B
$2.09M 0.08%
+20,000
New +$2.4M
1 2
3
4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return

PFM Health Sciences's Q2 2023 Portfolio in Review

As of Q2 2023, PFM Health Sciences held 96 positions worth $2.58B, up 14% from $2.26B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

PFM Health Sciences deployed $159M of net new capital in Q2 2023, opening 19 new positions and adding to 23 existing holdings. Its largest new stake was Biogen: 198,334 shares worth $56.5M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was uniQure, an estimated $38.8M trimmed.

  • PFM Health Sciences's largest Q2 2023 buy was Biogen: 198,334 shares worth $56.5M.
  • PFM Health Sciences added most to Icon in Q2 2023, an estimated $31.7M increase.
  • PFM Health Sciences's biggest Q2 2023 reduction was uniQure, cutting an estimated $38.8M.
  • PFM Health Sciences fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $35.7M.
  • PFM Health Sciences's ten largest holdings make up 34% of its $2.58B portfolio in Q2 2023.
  • PFM Health Sciences opened 19 new positions and closed 13 in Q2 2023.
  • PFM Health Sciences's portfolio value rose 14% quarter-over-quarter to $2.58B.

Based on PFM Health Sciences's 13F filing for Q2 2023, filed 14 Aug 2023.